Vivos Inc. Achieves Record Growth in IsoPet® Animal Cancer Treatments in Q1 2025

Core Insights - Vivos Inc. reported a record-breaking first quarter for its IsoPet Animal Cancer Division, with a 150% year-over-year increase in treatment volume, highlighting its growing role in veterinary oncology [1][2] Group 1: Treatment Volume Surge - IsoPet treated 15 pets in Q1 2025, a 150% increase from Q1 2024, with a biweekly production schedule ensuring a steady supply of yttrium-90 (Y-90) hydrogel for targeted radiation [2] - Recent treatments included five pets in New Jersey and Texas, demonstrating the therapy's effectiveness in reducing tumors and improving quality of life [2] Group 2: Breakthrough Clinical Applications - IsoPet made significant advancements in equine oncology, treating four horses with ocular squamous cell carcinoma using direct cornea injections, a novel approach for this challenging condition [3] - Additional applications include palliative therapy for advanced equine jaw cancer and margin therapy post-tumor resection [3] Group 3: Clinic Expansion - Vivos Inc. activated three new certified clinics in Q1 2025, increasing the total to 14 clinics, with plans for further expansion to enhance access for pet owners [4] - The new clinics include specialized facilities for both small animals and equines, emphasizing the importance of trained veterinarians in the success of IsoPet [4] Group 4: Strategic Marketing and Community Engagement - IsoPet increased its presence at major veterinary conferences and utilized targeted newsletters and social media to drive treatment inquiries and community support [5] - Positive feedback from pet owners on social media highlights the effectiveness of IsoPet's non-surgical approach [5] Group 5: Market Positioning - The global veterinary oncology market, valued at $1.18 billion in 2023, is projected to grow at an 11.3% CAGR through 2030, driven by rising cancer diagnoses in pets [6] - IsoPet's minimally invasive therapy is well-positioned to meet this growing demand, offering a cost-competitive alternative to traditional radiation [6] Group 6: Leadership Perspective - The President & CEO of Vivos Inc. emphasized the transformative impact of IsoPet on veterinary oncology and the commitment to expanding access and exploring new applications [7][8]